Geron (GERN) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Geron (GERN) over the past year, gaining 2.4% versus a loss of 11.6%. Over five years, GERN leads with a -13.5% price change compared with -72.7% for LXRX. Geron is the larger company by market cap ($787.0 million vs $747.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GERN | LXRX |
|---|---|---|
| Share price | $1.23 | $1.68 |
| Market cap | $787.03M | $747.53M |
| 1-day change | +0.41% | -4.55% |
| YTD return | -7.58% | +46.09% |
| 1-year return | -11.59% | +2.44% |
| 5-year return | -13.48% | -72.73% |
| Forward P/E | 30.63 | — |
| EPS (TTM) | $-0.11 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.01 | $2.68 |
| 52-week low | $1.04 | $1.10 |
| Distance from 52-week high | -39.05% | -37.31% |
| Analyst consensus | none | buy |
| Avg. price target upside | +246.94% | +170.83% |
| Average volume | 10.06M | 2.91M |
| Shares outstanding | 642.47M | 444.96M |
| Employees | 258 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed GERN by 14.0 percentage points over the past year.
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
GERN vs LXRX FAQ
Which is bigger, Geron or Lexicon Pharmaceuticals?
Geron (GERN) is larger, with a market capitalization of $787.03M compared with $747.53M for Lexicon Pharmaceuticals (LXRX).
Which stock has performed better over the past year, GERN or LXRX?
LXRX returned +2.44% over the past 12 months, compared with -11.59% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Geron and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.